Cyclopharm Lands Top-20 US Hospital and Locked-In Pathway to 6 More Sites
Key Takeaways
Cyclopharm's Northwestern Medicine agreement secures a seven-site Technegas deal with a top-20 US hospital network, marking the company's entry into Chicago and accelerating its Midwest expansion strategy.
- Cyclopharm has signed a seven-site agreement with Northwestern Medicine, including one immediate Technegas installation at Northwestern Memorial Hospital, ranked among the top 20 hospitals in the United States.
- The deal marks Cyclopharm's entry into Chicago and the broader Midwest healthcare market, complementing its previously announced 11-site agreement with the University of Pennsylvania Health System on the East Coast.
- The IDN agreement structure provides a contracted pathway to deploy up to six additional installations across the Northwestern Medicine network, creating visible near-term revenue expansion opportunities.
- Each Technegas installation generates dual recurring revenue streams — ongoing consumables revenue per patient procedure and annual service and support fees — which multiply as sites are added.
Cyclopharm (ASX: CYC) has secured a seven-site agreement with Northwestern Medicine, a leading academic health system based in Chicago, Illinois. The Cyclopharm Northwestern Medicine agreement provides for one immediate Technegas installation at Northwestern Memorial Hospital, ranked among the top 20 hospitals in the United States according to U.S. News & World Report, plus up to six additional installations across the Northwestern Medicine network over time.
This marks Cyclopharm’s entry into Chicago, one of the largest and most strategically important healthcare markets in the US, and establishes a platform for broader expansion across the Midwest region.
Cyclopharm secures seven-site deal with top-20 US hospital network
The multi-site agreement with Northwestern Medicine represents a significant strategic win for Cyclopharm’s US commercial rollout. Northwestern Memorial Hospital’s ranking among the top 20 US hospitals provides clinical credibility and positions the company within a premier academic health system known for research-driven healthcare delivery.
The agreement structure includes one immediate Technegas installation at Northwestern Memorial Hospital in Chicago, with a contracted pathway to deploy up to an additional six installations across the Northwestern Medicine network over time. This expansion framework provides visibility into potential future revenue growth as the technology is adopted across multiple sites within the system.
As one of the premier academic health systems in the Midwest, Northwestern Medicine carries significant clinical influence. Securing this lighthouse institution creates a reference point for broader adoption across the Chicago market and surrounding region, opening pathways to additional healthcare providers seeking proven technologies deployed by leading academic centres.
When big ASX news breaks, our subscribers know first
What is an integrated delivery network and why does it matter for medical device companies?
Integrated delivery networks (IDNs) are large healthcare systems comprising multiple hospitals and clinical sites operating under unified management and administrative structures. These networks streamline decision-making processes by centralising procurement, technology adoption, and clinical protocol development across all affiliated locations.
For medical device companies like Cyclopharm, securing an IDN agreement creates an efficient pathway to scale adoption without negotiating separate commercial arrangements for each individual hospital or clinic. Once a technology is validated at one site within the network, expansion to additional locations follows established internal processes rather than requiring entirely new sales cycles.
This model aligns with Cyclopharm’s stated strategy of targeting large integrated healthcare networks to drive scalable market penetration in the US. The Northwestern Medicine agreement exemplifies this approach, combining an initial installation with a contracted framework for system-wide expansion.
Revenue model mechanics
Each Technegas installation generates two distinct revenue streams for Cyclopharm:
- Ongoing consumables revenue per patient procedure as the technology is used in clinical practice
- Annual service and support fees for each installed unit
This dual revenue structure creates a recurring baseline from service fees whilst consumables revenue scales with patient procedure volumes at each site. As Northwestern Medicine expands from one installation to potentially seven sites across the network, both revenue streams multiply accordingly.
US expansion strategy gains momentum with second major IDN agreement
The Northwestern Medicine agreement follows Cyclopharm’s previously announced multi-site deal with the University of Pennsylvania Health System (UPHS), which covers 11 clinical locations. Together, these agreements demonstrate accelerating execution of the company’s US expansion strategy and validation of its lighthouse institution approach.
The two IDN agreements provide geographic diversification across major US metropolitan markets. UPHS establishes presence on the East Coast centred on Philadelphia, whilst Northwestern Medicine opens the Midwest market anchored by Chicago. This geographic spread reduces regional concentration risk and positions Cyclopharm across multiple high-density healthcare markets.
| Healthcare System | Location | Total Sites | Status |
|---|---|---|---|
| Northwestern Medicine | Chicago, Illinois (Midwest) | 7 sites | One immediate installation, up to 6 additional |
| University of Pennsylvania Health System | Philadelphia, Pennsylvania (East Coast) | 11 clinical locations | Multi-site agreement |
Both agreements target nationally recognised academic health systems with significant clinical influence within their respective regions. This lighthouse strategy aims to establish Technegas as a validated technology at institutions that set clinical standards, potentially accelerating adoption by other healthcare providers seeking proven solutions deployed by leading academic centres.
Strategic pillars driving US rollout
According to the company’s announcement, Cyclopharm’s US strategy focuses on three core pillars, all of which the Northwestern Medicine agreement addresses:
- Establishing leading reference sites at top-tier academic health systems that influence clinical practice standards
- Building regional density across key metropolitan markets to create service and support efficiencies
- Expanding across large integrated healthcare networks to scale adoption through contracted multi-site agreements
The Northwestern Medicine deal advances each pillar simultaneously. It establishes a top-20 ranked hospital as a reference site, creates density in the Chicago metropolitan market, and leverages the IDN structure for contracted expansion across up to seven total sites.
The next major ASX story will hit our subscribers first
CEO highlights Chicago as critical market foothold
Management commentary emphasised the strategic importance of establishing presence in Chicago as a gateway to broader Midwest expansion.
James McBrayer, Managing Director and CEO
“Securing a multi-site agreement with Northwestern Medicine represents another significant milestone in our US expansion and follows immediately on the momentum generated by our UPHS announcement. Northwestern is a premier academic health system and a recognised leader in clinical excellence. Establishing Technegas in Chicago provides us with a critical foothold in a major US healthcare market and positions us strongly for broader expansion across the Midwest. Agreements of this nature, combining an initial installation with a contracted pathway to multiple sites, are central to our strategy of driving scalable, recurring revenue growth in the US.”
The CEO’s comments reinforce the importance of lighthouse institutions in driving broader market adoption. By securing Northwestern Medicine as a reference site, Cyclopharm aims to accelerate clinical validation and create demonstration cases that support expansion to additional healthcare providers across the region.
The emphasis on scalable, recurring revenue growth highlights the commercial model underpinning the US expansion. As each IDN agreement progresses from initial installation to system-wide deployment, the revenue base expands without proportional increases in customer acquisition costs.
What comes next
The Northwestern Medicine agreement establishes a platform for broader Midwest regional expansion, with Chicago serving as the anchor market. The contracted pathway from one installation to potentially seven sites provides revenue visibility as the technology moves through the adoption curve within the network.
This follows the pattern established with UPHS, where the initial agreement covers 11 clinical locations, demonstrating how IDN structures can accelerate deployment once the technology is validated. The company’s strategy of securing similar multi-site agreements with leading academic health systems aims to replicate this expansion model across multiple US regions.
With two major IDN agreements now in place covering East Coast and Midwest markets, Cyclopharm’s US footprint spans geographically diverse, high-density healthcare markets. The contracted expansion pathways embedded in these agreements reduce execution risk for near-term growth targets by providing structured deployment frameworks rather than relying solely on new customer acquisition.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to receive alerts the moment market-moving announcements hit the ASX.